This paper investigates the expression of the CREB1 gene in ovarian cancer (OV) by deeply excavating the gene information in multiple databases and the mechanism thereof. In short, we found that the expression of the CREB1 gene in ovarian cancer tissue was significantly higher than that of normal ovarian tissue. Kaplan–Meier survival analysis showed that the overall survival was significantly shorter in patients with high expression of the CREB1 gene than those in patients with low expression of the CREB1 gene, and the prognosis of patients with low expression of the CREB1 gene was better. The CREB1 gene may play a role in the occurrence and development of ovarian cancer by regulating the process of protein. Based on differentially expressed genes, 20 small-molecule drugs that potentially target CREB1 with abnormal expression in OV were obtained from the CMap database. Among these compounds, we found that naloxone has the greatest therapeutic value for OV. The high expression of the CREB1 gene may be an indicator of poor prognosis in ovarian cancer patients. Targeting CREB1 may be a potential tool for the diagnosis and treatment of OV.
How MoticEasyScan was used:
Tissue array slides (CJ2) containing human ovarian cancer, metastatic, and normal tissues were purchased from SuperBioChips Laboratories (Seoul, Republic of Korea). For immunohistochemistry (IHC), assays and scoring methods were performed as described . The slides were treated with anti-CREB1 antibody (1:100, A11063, ABclonal, Boston, MA, USA). All glass slides were digitized with an MoticEasyscan Digital Slide Scanner at ×40 (0.26 µm/pixel) with high precision (High precision autofocus). MoticEasyscan whole-slide images were viewed with DSAssistant and EasyScanner software at Li-Tzung Pathology Laboratory (Kaohsiung, Taiwan).